Regulations.gov document
Bristol Myers Products Inc.; Withdrawal of Approval of a New Drug Application for BUFFERIN…
Notice · FDA-2022-N-2796 · posted Jul 21, 2023
Key facts
| Document ID | FDA-2022-N-2796-0003 |
|---|---|
| Title | Bristol Myers Products Inc.; Withdrawal of Approval of a New Drug Application for BUFFERIN (Aspirin) Tablets |
| Document type | Notice |
| Subtype | Withdrawal |
| Agency | FDA |
| Docket | FDA-2022-N-2796 |
| Posted | Jul 21, 2023 |
| Federal Register citation | 88 FR 47147 |
| FR document number | 2023-15454 |
| Comment period opens | Jul 21, 2023 |
| Effective date | Jul 21, 2023 |
At a glance
- 1–9 Pages
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: